NEW YORK, May 21 - Cambridge Antibody Technology will partner with Immunex to jointly discover and develop new antibody-based drugs for treating inflammation, the companies said Monday. 

The agreement calls for Immunex to provide two undisclosed protein drug targets and for CAT to develop antibodies to those targets using its antibody phage display and screening technologies. Immunex is to bear responsibility for pre-clinical evaluation, clinical trials, and product commercialization. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.